GLP-1 agonists · mechanism / efficacy / real costGLP-1 减肥药 · 机制深入、效力、真实代价

Place · Level 3 · Pharmacology

Semaglutide -14.9% · Tirzepatide -20.9% · 但停药反弹 2/3 · 副作用 + 肌肉流失真实存在 · 不是奇迹, 是长期承诺

What they are · gut hormone, pharmacologized

Stop 1/5

GLP-1 是什么 · 肠道激素的药物化

glucagon-like peptide-1: A gut hormone released after eating that makes you feel full and helps lower blood sugar. (glucagon-like peptide-1) is a gut hormone, not a synthetic invention. Secreted by intestinal L-cells (mainly distal ileum + colon) after meals; its native half-life is only 1-2 minutes (rapidly degraded by DPP-4 enzyme).

Four native actions of GLP-1:

Insulin secretion (glucose-dependent) — only fires when glucose is high, unlike sulfonylureas which push insulin indiscriminatelyGlucagon suppression — reduces hepatic glucose outputDelayed gastric emptying — food stays in stomach longer, prolonging satietyCentral satiety — acts on hypothalamus + brainstem NTS (nucleus tractus solitarius), directly dampening appetite signals
Key pharmacological breakthroughs:

Exenatide (2005, from lizard saliva): 1st gen, twice-daily injectionLiraglutide (Victoza / Saxenda, 2010/2014): fatty-acid side chain → 13 h half-life, once-dailySemaglutide (Ozempic / Wegovy, 2017/2021): further extended → 165 h half-life, once-weekly injectionTirzepatide (Mounjaro / Zepbound, 2022/2023): dual agonist (GLP-1 + GIP), once-weekly, more potent
Indication evolution:

Originally type-2 diabetes (Ozempic / Mounjaro brand names)From 2021, FDA-approved for chronic weight management (Wegovy / Zepbound brands): BMI ≥ 30, or BMI ≥ 27 + at least 1 weight-related comorbidity (T2D / hypertension / dyslipidemia / OSA / cardiovascular disease)
Key takeaways:

This is not a new mechanism — it is pharmacological amplification of an existing human hormone, stretching half-life from 1 minute to 165 hoursNot a 'fat burner' or 'metabolic accelerator' — the core action is central satiety so you eat lessOrder of launch: diabetes first, weight management second — the weight-loss effect was observed as a 'side product' before high-dose weight-loss indications were developed

Read story

本站提供科普与一般性建议，不替代医师诊断或处方；有症状或正在服药请咨询合格医师。 Educational content, not medical advice — consult a clinician for diagnosis or treatment.

Back